PMID: 9440059Jan 24, 1998Paper

Is Helicobacter pylori infection a risk or protective factor for mucosal lesions development in patients chronically treated with acetylsalicylic acid?

Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
H KordeckiD Pilecka

Abstract

The interaction between ASA and H.p. as the strongest irritants to gastric mucosa has not been sufficiently documented to date. The aim of our study was to evaluate the frequency of mucosal lesions in stomach and duodenum and the frequency of H.p. infection in patients suffering from IHD and chronically taking ASA. We evaluated the number of mucosal lesions and the incidence rate in relation to the daily dose of ASA. We examined 96 with IHD treated with ASA in doses: 75, 150 or 300 mg per day. We assessed the number of mucosal lesions and H.p. status. The control groups included 80 patients treated for IHD who did not take ASA and 50 patients who did not suffer from IHD. The highest rate of mucosal lesions we found in the group of patients with IHD treated with ASA: 62% vs 41% in patients not using ASA and 8% in the control group. We did not find any essential difference in mucosal lesions occurrence between patients treated with 75 or 150 and 300 mg per day. In patients with IHD using ASA the frequency of H.p. infection was higher in comparison to patients not receiving ASA (68% vs 47%) and to control group (68% vs 26%). ASA users infected with H.p. had more mucosal lesions (75%) in comparison to those not using ASA (47%). Our...Continue Reading

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.